Insider Selling: Progyny (NASDAQ:PGNY) EVP Sells $15,022.92 in Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 599 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $25.08, for a total value of $15,022.92. Following the sale, the executive vice president directly owned 82,378 shares in the company, valued at $2,066,040.24. This trade represents a 0.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Allison Swartz also recently made the following trade(s):

• On Wednesday, June 3rd, Allison Swartz sold 1,199 shares of Progyny stock. The stock was sold at an average price of $25.02, for a total value of $29,998.98.

Progyny Price Performance

Progyny stock opened at $25.86 on Monday. The stock has a market capitalization of $2.03 billion, a price-to-earnings ratio of 33.58, a PEG ratio of 2.28 and a beta of 1.03. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $28.75. The business has a fifty day moving average price of $20.58 and a 200-day moving average price of $22.26.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.47 million. During the same quarter last year, the firm earned $0.17 EPS. The business’s quarterly revenue was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, equities research analysts anticipate that Progyny, Inc. will post 1.07 earnings per share for the current fiscal year.

Progyny announced that its Board of Directors has authorized a share buyback program on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 10.3% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on PGNY shares. Citizens Jmp boosted their price target on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research note on Monday, May 11th. KeyCorp dropped their price target on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Jefferies Financial Group restated a “buy” rating and set a $30.00 price target on shares of Progyny in a research note on Friday, March 6th. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. Finally, Barclays lifted their price target on Progyny from $23.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.67.

Institutional Trading of Progyny

Large investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new stake in Progyny during the 4th quarter valued at about $25,000. Federated Hermes Inc. grew its stake in Progyny by 147.3% during the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after purchasing an additional 819 shares during the last quarter. Hantz Financial Services Inc. grew its stake in Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after purchasing an additional 742 shares during the last quarter. Quarry LP grew its stake in Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after purchasing an additional 3,427 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in Progyny during the 2nd quarter valued at about $77,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.